Triage. Sort. Prioritize.
cmTriage® from CureMetrix is the first FDA-cleared software intended to provide a notification triage code to the radiologist’s mammography worklist based on the presence of a suspicious region of interest found by the underlying algorithm. This workflow optimization tool enables a radiologist to customize their 2D mammogram or mammography worklist based on cases that may need immediate attention.
Currently, viewing stations do not allow for intelligent sorting and prioritizing of cases – a radiologist can only sort based on name, date of image acquisition, time of image acquisition, etc. With cmTriage, a radiologist can sort and prioritize cases in their worklist based on the presence of suspicious regions of interest found by the underlying algorithm. This gives the radiologist the opportunity to tackle the more difficult mammograms with a heightened awareness, or perhaps to assign those cases to the specialist best suited to interpret them.
cmTriage can also be used to optimize clinical protocol and maximize a clinic’s utilization of resources. *cmTriage is designed to be compatible with most screening mammography equipment. Additionally, cmTriage is cloud-based so there are no added systems to install or buttons to click. The software is both DICOM and HIPAA compliant and no PHI ever leaves the hospital.
- Works across all breast densities
- Works with both mass and calcifications
- According to the Breast Cancer Surveillance Consortium (BCSC), the average sensitivity of a radiologist is 84.4% and on average they are recalling 9.6% of cases. cmTriage only flags 8.2% of cases at the same sensitivity1
- At the increased default sensitivity of 93%, cmTriage will still only identify 24% of your worklist as suspicious while also potentially catching 1 to 2 more cancers per 1,000 screening cases
cmTriage is FDA cleared as a notification-only, parallel workflow tool used to identify specific patients to a radiologist based on the presence of at least one suspicious finding to support standard of care image interpretation. It is easy to implement clinically and enables a radiologist to prioritize the most suspicious cases and optimize their workflow.
*Please refer to the Operator’s Manual for the specific details
- NCI-funded Breast Cancer Surveillance Consortium (HHSN261201100031C). Downloaded
9/5/2018 from the Breast Cancer Surveillance Consortium Web site –
- FDA 510(k) Submission #K183285
*Disclaimer: cmTriage® is FDA-cleared for commercial use in the U.S and ANVISA-cleared for commercial use in Brazil.